Search clinical trials for: Infanrix IPV

Total 1785 results

GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
Dalhousie University
IWK Health Centre; MCM Vaccines B.V.

Completed

Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age

Infant Immunizations

Canada
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Russian Federation
GlaxoSmithKline

Withdrawn

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Sweden
GlaxoSmithKline

Completed

Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea

Tetanus | Diphtheria | Acellular Pertussis | Diphtheria-Tetanus-acellular Pertussis Vaccines | Poliomyelitis

Korea, Republic of
GlaxoSmithKline

Completed

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Vietnam
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

China
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule

Infections, Streptococcal

Slovakia, Sweden, Denmark, Norway
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae Vaccines

Spain, Germany, Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

Meningococcal Infection

Mexico, Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Tetanus | Diphtheria | Acellular Pertussis | Haemophilus Influenzae Type b

China
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

Healthy | Infant

Germany
University of Primorska
Biostile d.o.o.

Completed

Clinical Trials of Five Different Food Supplements With Restriction Diet in Adults (FOODSU)

Inflammation | Hypertension | Hypercholesterolemia | Overweight and Obesity

Slovenia
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
Aga Khan University
National Institutes of Health (NIH); Centers for Disease Control and Prevention and other collaborators

Completed

Polio End-game Strategies - Poliovirus Type 2 Challenge Study

Poliomyelitis

Pakistan
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Peru
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis

Mexico
GlaxoSmithKline

Completed

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Polio

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
Vaxtrials S.A.
Bill and Melinda Gates Foundation

Completed

Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life (IPV005)

Polio

Panama
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Panama, Mexico, Colombia
Centers for Disease Control and Prevention, China
World Health Organization; Hubei Provincial Center for Disease Control and... and other collaborators

Completed

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine (IPV)

Poliomyelitis

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

Colombia, Costa Rica
International Centre for Diarrhoeal Disease Research...
World Health Organization

Recruiting

Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh

Poliomyelitis

Bangladesh
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study (fIPV)

Poliomyelitis

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Colombia, Costa Rica
GlaxoSmithKline

Completed

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh

Terminated

Immunogenicity of Intramuscular and Intradermal IPV (IM and ID IPV)

Poliomyelitis

Bangladesh
GlaxoSmithKline

Completed

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
Sanofi Pasteur, a Sanofi Company

Completed

Database Surveillance Safety Study of PENTACEL® Vaccine

Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae

United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Tetanus | Diphtheria | Acellular Pertussis

Korea, Republic of
Sinovac Biotech Co., Ltd

Completed

An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses

Poliomyelitis

China
Sinovac Biotech Co., Ltd

Completed

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Poliomyelitis

China
Takeda

Terminated

IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

Poliomyelitis

Panama
GlaxoSmithKline

Completed

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Infections, Streptococcal

Singapore, Malaysia
GlaxoSmithKline

Completed

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Diphtheria

Spain, Germany, Italy
GlaxoSmithKline

Completed

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Infections, Streptococcal

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type B Infection

Mexico
GlaxoSmithKline

Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

Infections, Meningococcal

Austria, Greece
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland

Search clinical trials for: Infanrix IPV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations